Lipedema Research Updates
Largest observational study to date on ultrasound-assisted liposuction
In May 2026 in the journal of Plastic and Reconstructive Surgery, the largest observational study on ultrasound-assisted liposuction (UAL) to date was published. The protocol involved a two-stage UAL on lower extremity lipedema followed by 6 months of conservative treatment. Results showed an average of 6.4 cm decrease in diameter, significant decreases in pain and sensitivity, and high patient satisfaction at 12 months post-operative.
Hersant B, de Clermont-Tonnerre E, Argentino G, et al. Observational study of ultrasound-assisted liposuction for lower limb lipedema on 191 female patients. Plast Reconstr Surg. 2026;157(5):751e-762e. doi:10.1097/PRS.0000000000012217.
Potential benefit from GLP-1 exenatide
A June 2026 review of studies on GLP-1 receptor agonists and lipedema from the journal Dermatologic Surgery found one small uncontrolled case series showed direct evidence of reduced pain and limb volume in patients with lipedema taking exenatide. Though no direct evidence on tirzepatide and lipedema has been established, translational evidence suggests that lymphatic and anti-fibrotic effects are relevant to lipedema.
Mohseni Y, Vazirnia A, Minokadeh A, Amron DM, Coleman WP 3rd. Targeting inflammation and fibrosis in lipedema: the potential role of glucagon-like peptide-1 receptor agonist therapies. Dermatol Surg. 2026;52(6S). doi:10.1097/DSS.0000000000005172.
How GLP-1 receptors affect the lymphatics
A June 2026 study in Microcirculation studied the effects of GLP-1 receptors on the lymphatic system. They found, in mouse models, GLP-1 receptors are enriched in lymphatic endothelial cells, and semaglutide improved lymphatic vessel pumping activity via vasodilation, suggesting another mechanism of benefit of GLP-1 receptor agonist medications in lipedema.
Schulz ME, Akerstrom VL, Dayan JH, Castorena-Gonzalez JA. GLP-1 receptors are enriched in the lymphatic endothelium and their pharmacological activation with semaglutide improves the pumping capacity of lymphatic vessels. Microcirculation. 2026;33(5). doi:10.1111/micc.70070.
Endostatin as a key differentiator in lipedema vs. obesity
July 2026 study by Kempa et al looked at 23 premenopausal woman with lipedema with 23 BMI-matched controls and found that endostatin was a key standout. Endostatin inhibits angiogenesis suggesting altered blood vessel formation. Lipedema appears to have lower endostatin than BMI-matched obese controls, suggesting a potentially distinctive alteration in vascular regulation. Interestingly, most of the other markers, including inflammatory markers, were not different.
Reduced Serum Endostatin in Premenopausal Women with Lipedema Suggests Altered Vascular Homeostasis
Kempa S, Weiss TS, Tews HC, et al. Reduced serum endostatin in premenopausal women with lipedema suggests altered vascular homeostasis. Diseases. 2026;14(7):168. doi:10.3390/diseases14070251
No evidence for benefit of gestrinone in lipedema
A review looked at past studies to see if there was evidence of a clinical benefit of the drug gestrinone (which has androgenic, anti-progestogenic, anti-estrogenic properties and is sometimes used in the treatment of endometriosis) and did not find evidence to support any benefit in lipedema.
Lima MF. Gestrinone, lipedema, and the limits of theoretical extrapolation in clinical practice: a critical narrative review. J Vasc Bras. 2026;25:e20250240, DOI 10.1590/1677-5449.202502401
The Four-Pathway Framework
Researchers recently proposed a new framework for understanding lipedema as a condition influenced by several interacting biological pathways rather than a single cause. The framework looks at hormonal changes, metabolic factors, gynecologic/endocrine factors, and the characteristics of the fat and connective tissue itself, while emphasizing that many of these connections are still hypotheses that need further research.
Viana DPC, Invitti AL, Schor E. Lipedema as a hormone-sensitive stromal disorder: a four-pathway translational framework. Front Cell Dev Biol. 2026;14:1903835. doi:10.3389/fcell.2026.1903835.
The Lipedema Common Case Report Form (CCRF) established
CCRF is a standardized research tool designed to help researchers collect the same types of information about people with lipedema. By making data more consistent across studies, it should make it easier to compare research, identify meaningful subtypes, and eventually build stronger evidence about diagnosis and treatment.
Galia S, Crescenzi R, Kruppa P, et al. The lipedema common case report form as a research tool: standardizing lipedema data collection. Front Glob Womens Health. 2026;7:1833913. doi:10.3389/fgwh.2026.1833913.
The lipedema research world is an exciting place! This page is updated approximately quarterly. It was started in 2026 and will gradually get some back-fill on earlier studies. Are you a researcher and have an addition or comment? E-mail hello@lipedemaND.com
Spring 2026 Updates
The Lipedema World Alliance published a Delphi consensus-based position paper January 2026
in Nature Communications representing experts from 19 countries. 59 consensus statements were reached adding to the framework of definitions and treatments for lipedema.
Kruppa P, Crescenzi R, Faerber G, et al. Lipedema World Alliance Delphi consensus-based position paper on the definition and management of lipedema: results from the 2023 Lipedema World Congress in Potsdam. Nat Commun. 2026;17(1):427. doi:10.1038/s41467-025-68232-z. PMID: 41519859.
A Comparison Study of Wet vs. Dry Liposuction
This study looked at 106 consecutive surgeries showed both were effective, but the wet technique demonstrated greater potential in pain reduction and better aesthetic satisfaction at 12 months post-surgery, with shorter operative times.
Thiry M, Schiraldi L, Guiotto M, et al. A single center retrospective observational study on 106 consecutive lipedema surgeries: defining the ideal surgical approach. J Plast Reconstr Aesthet Surg. 2026. PMID: 41564589.
Future potential biomarker identified January 2026
A groundbreaking study identified AKT1 as a site of epigenetic alterations that result in impaired cellular energy metabolism in the pathophysiology of lipedema. AKT1 may serve as a biomarker and possibly even avenue for treatment in the future.
Santella B, Salvati A, Papp A, D’Ursi A, Memoli D, Mingo M, Pulai C, Marino C, Rastrelli L, D’Elia M, Nassa G, Schiavo L. Epigenetic alterations of AKT1 orchestrate a metabolic reprogramming in advanced lipedema: translational insights from an integrated multi-omics study. J Transl Med. 2026;24(1):265. doi:10.1186/s12967-026-07726-w.
A systematic review on lipedema treatments published in January 2026 rated tumescent liposuction as a grade 1 recommendation
Tumescent liposuction was associated with the strongest evidence for sustained symptom improvement, mobility, and quality of life. Conservative therapies examined in the study that were associated with reduced pain and swelling included the ketogenic or Rare Adipose Disorders (RAD) diets, compression therapy, and aquatic exercise.
Lipedema Diagnosis, Clinical Manifestations, and Therapeutics: A Systematic Review.
Vazirnia A, Smart DR, Mohseni Y, Amron DM. Lipedema diagnosis, clinical manifestations, and therapeutics: a systematic review. Int J Dermatol. 2026. PMID: 41498193.
